Floatz logo

MODERNA COVID-19 VACCINE RNA

Juvenile Dermatomyositis (JDM)

National Institute of Allergy and Infectious Diseases (NIAID)vaccinePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Juvenile Dermatomyositis (JDM) cohort.

Asset / SponsorPhaseRating
JNJ-78436735
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2CCC
METHOTREXATE
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2CCC
Monovalent [B.1.351] Cov2 Pres Dtm-As03
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2CCC
Tozinameran
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2CCC
bnt162b2
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2CC

Same molecule, other indications

MODERNA COVID-19 VACCINE RNA is also rated in:

secondary progressive multiple sclerosisDormant
B
Indicative ·
62 / 100
View asset →
AL amyloidosisDormant
CCC
Indicative ·
55 / 100
View asset →
neoplasmDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →